Elevai Corp (ELAB) - מקדם חוב לטווח ארוך להון

Elevai Labs Inc. (ELAB) is implementing ESG principles by replacing microplastics with biodegradable materials and reducing CO2 emissions. Despite the patent protection of its formulas, the low barrier to entry in the cosmeceuticals sector forces the company to invest heavily in promotion. The price history shows that the indicator is 0.27. The business relies on the supply of exosomal products to dermatological centers, targeting growing demand in the anti-age segment.

This indicator determines the share of long-term debt within the equity structure to assess financial stability. By analyzing the long-term debt-to-equity ratio, an investor evaluates the balance between leveraged financing and business autonomy. For Elevai Labs Inc. (ELAB), this is critical when funding costly dermatological research and patenting therapy methods. A low debt load confirms the company's ability to overcome technological barriers. This metric serves as a gauge of the asset's reliability in stress scenarios.